The partnership is aimed at exploring potential new therapies encompassing autoimmune, infectious and idiopathic disorders, using SAB’s DiversitAb platform
SAB Biotherapeutics, a clinical-stage biopharmaceutical company, has signed various partnership and option agreements with CSL Behring, a developer and manufacturer of protein-based therapies.
The company said that the collaboration is aimed at exploring potential new therapies that address the challenging autoimmune, infectious and idiopathic disorders, using its DiversitAb platform.
SAB Biotherapeutics president CEO and co-founder Eddie J Sullivan said: “We are excited that CSL Behring has chosen to work with SAB Biotherapeutics to explore new immunotherapies leveraging our technology platform.
“We believe combining our unique human antibody development and production capabilities with CSL Behring’s established immunoglobulin franchise and vast expertise in biopharmaceutical development will broaden therapeutic possibilities.”
SAB and CSL Behring will conduct research program, sharing related costs
SAB said that its DiversitAb platform has been developed leveraging advanced genetic engineering, to naturally and quickly manufacture human antibodies in large amounts, preventing the use of human donors.
In addition, the partnership and option agreements signed by the company include a research program to investigate potential new source for human immunoglobulin G (IgG).
Human IgG is used for immunological and neurological diseases including primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), guillain-barre syndrome (GBS), immune thrombocytopenic purpura (ITP), and multifocal motor neuropathy (MMN).
Under the initial phase of the collaboration, SAB and CSL Behring are expected to share research program and associated expenditure in 2020. The partnership may lead to more development and commercialization agreements in future.
CSL Behring offers plasma-derived and recombinant therapies encompassing bleeding disorders, fluid replacement, hereditary angioedema, immunoglobulin, pulmonary, and wound healing.
CSL Behring research senior vice president Andrew Nash said: “SAB Biotherapeutics has developed a very interesting and novel platform for the production of human immunoglobulins. CSL Behring is committed to the continuous development of innovative therapies that address unmet needs for patients with rare and serious diseases.
“This collaboration will provide both companies an opportunity to explore the potential of these new approaches to positively impact areas of need.”